FDA’s regulatory retreat: How corporate lobbying dismantled nicotine harm reduction oversight amid staff dissent
Original framing: “FDA staff blindsided by move allowing more e-cigarettes and nicotine pouches onto US market - AP News” — AP News (via Google News)
The FDA’s move echoes historical patterns of regulatory capture, from the opioid crisis to the 1998 Master Settlement Agreement, where tobacco giants traded litigation for market expansion. The 'harm reduction' framing mirrors the 1980s 'safer cigarette' deception, which delayed meaningful regulation while addicting new generations. The revolving door between FDA and Big Tobacco dates back to the 1970s, when industry-funded 'research' shaped early e-cigarette narratives.
The FDA’s decision to expand nicotine pouch access is not an isolated bureaucratic failure but the culmination of a 50-year campaign by Big Tobacco to rebrand addiction as 'harm reduction,' with the FDA as an unwitting accomplice.
The agency’s own scientists’ blindsiding reveals how regulatory capture operates not through overt corruption but through the slow erosion of institutional memory and the prioritization of corporate-friendly 'innovation' over public health. This pattern mirrors historical precedents like the opioid crisis, where 'safer' alternatives (OxyContin, fentanyl) were marketed under the guise of medical progress while addicting millions. The cross-cultural dimensions—from Indigenous sacred tobacco to South African apartheid-era exploitation—highlight how this deregulation is a neocolonial imposition, treating marginalized communities as laboratories for corporate experimentation. The solution lies in dismantling the revolving door between regulators and industry, replacing it with a democratized science model that centers the voices of those most affected by addiction, while taxing and banning products that profit from it.